Tuesday, 3 November 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Business Update

Shivalik Rasayan Business Update

Shivalik Rasayan achieved USFDA Complete Assessment for its Avapritinib API Drug Master File. The API is used in Sanofi's GIST treatment Ayvakit.

Source

BSE filing, NSE: SHIVALIK. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Shivalik Rasayan Ltd: key numbers

Share price
₹288.85
Market cap
₹463.1 Cr
Revenue (annual)
₹368.0 Cr
Net profit (annual)
₹12.40 Cr
P/E (TTM)
33.9×Sector 33.6×
Promoter holding
46.54%-0.83% QoQ
FII holding
0.72%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Shivalik Rasayan Ltd

All →
16:16 IST BSE
Fund Raise

Shivalik Rasayan Fund Raise of ₹30.75 Cr

Shivalik Rasayan allotted 2,82,000 equity shares and 9,47,990 warrants on a preferential basis, raising Rs. 30.75 Crore in new capital for the company.

Value
₹30.75 Cr

Other business update announcements

All →